All Transactions - Bryan, Garnier & Co

Our transactions

Bryan, Garnier & Co offers a complete range of investment banking services, from growth financing to mergers and acquisitions.

Bryan, Garnier & Co acts as Sole Financial Advisor to Ingenico Group on the carve-out of its French healthcare business to Andera Partners

Bryan, Garnier & Co accompanies DBV on its $143 million NASDAQ Follow-on

Bryan, Garnier & Co acts as Joint Bookrunner to BioNTech on its $150 million Nasdaq Initial Public Offering

Bryan, Garnier & Co acts as Sole Financial Advisor to Keensight Capital on its majority investment in Geodesial

Bryan, Garnier & Co acts as Joint Bookrunning Manager on Celyad’s $20 million global equity offering

Bryan, Garnier & Co acts as Sole Financial Advisor to Inotrem on its €39 million Series B Fundraising

Bryan, Garnier & Co acts as Sole Financial Advisor to road freight management software solutions provider OMP Informatique Transport on its sale to NewAlpha Verto

Bryan, Garnier & Co acts as Sole Advisor to Argos Wityu and the real estate management software provider Salvia Developpement on its sale to Total Specific Solutions (TSS)

Salvia transaction tombstone image

Bryan, Garnier & Co acts as Sole Financial Advisor to IK Investment Partners on its acquisition of Recocash

Bryan, Garnier & Co acts as Sole Financial Advisor to the Belgian consultancy firm Intys on its equity investment from Omnes

Bryan, Garnier & Co acts as Sole Financial Advisor to the audio tech company Arturia on its capital reorganisation led by EMZ Partners

Bryan, Garnier & Co acts as Sole Financial Advisor to drone software leader Unifly on a €17 million capital raise

Bryan, Garnier & Co acts as Sole Bookrunner on Carbios €14.5million Private Placement

Bryan, Garnier & Co makes significant move into the Nordics with the acquisition of Beringer Finance

Bryan, Garnier & Co acts as Joint Bookrunner to Genfit on its $155.4 million Nasdaq Initial Public Offering

Bryan, Garnier & Co acts a Sole Financial Advisor to Biolectric on the sale of a 60% stake to Ackermans & van Haaren alongside founder and CEO

Bryan, Garnier & Co acts as Sole Financial Advisor to Canon on the sale of its German document outsourcing services division to ASC Investment

Bryan, Garnier & Co acts as Sole Financial Advisor to B2B data analytics and Real Estate information provider Explore on its sale to Activa Capital

Bryan, Garnier & Co acts as Sole Financial Advisor to HighLife on its €32 million Series B Fundraising

Bryan, Garnier & Co acts as Sole Financial Advisor to life insurance platform Quality Insurance Services on its sale to CNP Assurances

Prima Solutions and Effisoft announce their merger to bolster global leadership in providing insurance solutions

Bryan, Garnier & Co leads a $80 million Private Placement for European Blockchain Unicorn Bitfury

Bryan, Garnier & Co advises tado° on its USD 50 million financing round – attracting international investment from Amazon, E.ON, Total, Energy Innovation Capital, WS Capital and the European Investment Bank to bring total funding to USD 102 million

Bryan, Garnier & Co acts as Sole Financial Advisor to Sword Group SE on the divestiture of its wholesale finance software division, Sword APAK, to Sopra Banking Software Ltd

Bryan, Garnier & Co advises Prima Solutions and The Carlyle Group on the acquisition of ICOD

Bryan, Garnier & Co acts as Sole Financial Advisor to SaaS digital customer platform vendor Dimelo on its sale to Nasdaq-listed RingCentral

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for MedinCell’s €30 million Euronext Paris IPO

Bryan, Garnier & Co acts as Sole Financial Advisor to SmartMeUp on its sale to Magneti Marelli

Bryan, Garnier & Co advises Latour Capital on the acquisition of a majority stake in Sogetrel

Bryan, Garnier & Co acts as Sole Financial Advisor to Montagu Private Equity on the acquisition of Maincare Solutions

Bryan, Garnier & Co acts as Financial Advisor to Blueberry Therapeutics on its £10 million Series B Fundraising

Bryan, Garnier & Co acts as Joint Bookrunner on Materialise’s USD45 million Follow–On Equity Offering on Nasdaq

Bryan, Garnier & Co advises TxCell in its strategic review and subsequent EUR72 million sale to Sangamo Therapeutics to create a CAR-Treg leader

Bryan, Garnier & Co acts as Sole Bookrunner on ASIT biotech EUR12 million Convertible Bond Placement

Bryan, Garnier & Co advises Marquetis & Co and its management on a sponsorless operation with Omnes

Bryan, Garnier & Co acts as Co-Manager on Canopy Growth’s benchmark CAD500 million Convertible Bond New Issue

Bryan, Garnier & Co advises Picturae on its sale to Karmijn – contributing to the preservation of cultural heritage

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Voluntis’ IPO, the first ever listing of a digital therapeutics company raising EUR30.1 million

Bryan, Garnier & Co acts as Lead Manager on Medigene’s EUR48.3 million offering

Bryan, Garnier & Co advises ORPEA Group on the acquisition of Woonzorgnet B.V. in the Netherlands

Bryan, Garnier & Co acts as Joint Global Coordinator on Celyad’s EUR46.1 million global equity offering

Bryan, Garnier & Co acts as Sole Financial Advisor to Cyclopharma on its sale to Curium Pharma

Bryan, Garnier & Co acts as Sole Financial Advisor to Conduent in the sale of their off-street parking business to Andera Partners

Bryan, Garnier & Co acts as Sole Financial Advisor to Art-Event Group on its merger with Alive Groupe

Bryan, Garnier & Co advises 21net on its sale to Alstom – bringing WiFi connectivity to high-speed trains

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Medartis’ IPO CHF142.6 million on SIX Swiss Exchange

Bryan, Garnier & Co part of bulge bracket syndicate for DBV $150 million Follow-on

Bryan, Garnier & Co advises Bone Therapeutics on its €19.45 million convertible bond placement

Bryan Garnier & Co acts as Global Coordinator for Biom’Up’s financing representing a total amount of more than €40 million

Bryan, Garnier & Co acts as Placement Agent for Moderna